Skip to Content

PepGen, Inc.

Securities Class Action

  • Date:
  • 8/8/2025
  • Company Name:
  • PepGen, Inc.
  • Stock Symbol:
  • PEPG
  • Class Period:
  • FROM 3/7/2024 TO 3/3/2025
  • Status:
  • Filed
  • Filing Date:
  • 6/9/2025
  • Court:
  • U.S. District Court: Eastern District of New York

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against PepGen, Inc. (“PepGen” or the “Company”) (NASDAQ: PEPG) in the United States District Court for the Eastern District of New York on behalf of all persons and entities who purchased or otherwise acquired PepGen securities between  March 7, 2024 and March 3, 2025, both dates inclusive (the “Class Period”). Investors have until August 8, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) PGN-EDO51 was less effective and safe than Defendants had led investors to believe; (ii) the CONNECT2 study was dangerous or otherwise deficient for purposes of U.S. Food and Drug Administration ("FDA") approval; (iii) as a result of all the foregoing, PepGen was likely to halt the CONNECT2 study, and PGN-EDO51's clinical, regulatory, and commercial prospects were overstated; and (iv) as a result, Defendants' public statements were materially false and misleading at all relevant times.

If you purchased or otherwise acquired PepGen shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out the form below. There is no cost or obligation to you.
Contact Instructions
Please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com with any questions about the case.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in PepGen. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: